Sam Brusco, Associate Editor03.18.22
Electromedical Products International (EPI), a medical device engineering and manufacturing firm using cranial electrotherapy stimulation (CES) for mental and pain disorders, has acquired Pulvinar Neuro, a firm that develops closed-loop and other novel brain stimulation solutions to treat various mental health disorders.
EPI’slow-current, non-invasive CES and microcurrent electrical therapy (MET) can treat anxiety, insomnia, depression, and pain. Founded in 1981 by Dr. Daniel Kirsch, EPI’s FDA-cleared Alpha-Stim based devices are sold in over 50 countries.
The deal allows Pulvinar to accelerate development and commercialization of its transcranial current stimulation (tACS), individualized feedback stimulation, and cloud-enabled digital therapeutics for psychiatric and neurological conditions.
"We are very excited about adding Pulvinar and its team of brain stimulation and data science experts to our team,” EPI CEO Tracey B. Kirsch told the press. Pulvinar expands our scientific and research capabilities addressing non-invasive, drug free treatment solutions for anxiety, insomnia, depression and pain as well as other indications we plan to pursue for FDA clearance."
Pulvinar Neuro CEO Dr. Leah Townsend said, "I am looking forward to working with EPI to bring the next generation of personalized non-invasive brain stimulation to market, complementary with EPI's suite of devices, which we are confident will benefit millions of patients who are looking for effective and safe treatment options. I could not imagine a better partner than EPI with its decades of experience in developing and commercializing its technology."
EPI’slow-current, non-invasive CES and microcurrent electrical therapy (MET) can treat anxiety, insomnia, depression, and pain. Founded in 1981 by Dr. Daniel Kirsch, EPI’s FDA-cleared Alpha-Stim based devices are sold in over 50 countries.
The deal allows Pulvinar to accelerate development and commercialization of its transcranial current stimulation (tACS), individualized feedback stimulation, and cloud-enabled digital therapeutics for psychiatric and neurological conditions.
"We are very excited about adding Pulvinar and its team of brain stimulation and data science experts to our team,” EPI CEO Tracey B. Kirsch told the press. Pulvinar expands our scientific and research capabilities addressing non-invasive, drug free treatment solutions for anxiety, insomnia, depression and pain as well as other indications we plan to pursue for FDA clearance."
Pulvinar Neuro CEO Dr. Leah Townsend said, "I am looking forward to working with EPI to bring the next generation of personalized non-invasive brain stimulation to market, complementary with EPI's suite of devices, which we are confident will benefit millions of patients who are looking for effective and safe treatment options. I could not imagine a better partner than EPI with its decades of experience in developing and commercializing its technology."
